Columbia University Medical Center, New York, NY 10032, USA.
Cardiovascular Institute of the South, Houma, LA 70360, USA.
Future Cardiol. 2023 Mar;19(3):127-135. doi: 10.2217/fca-2022-0072. Epub 2023 Jun 19.
Paclitaxel drug-coated balloons (DCBs) have been shown to improve patency and lower revascularization rates compared with plain old balloon angioplasty. DCBs continue to evolve by improving balloon-coating techniques that minimize the quantity of particles washed off into the bloodstream while maximizing drug retention and vascular-healing profile. Against this backdrop, it is clear that the future of antiproliferatives for the superficial femoral artery will focus on enhancements in device coating materials that will improve the efficiency of drug delivery. The Ranger DCB system recently gained US FDA approval for use. This review discusses the background of DCBs and how the Ranger DCB builds on these previous platforms based on experimental and clinical data.
紫杉醇药物涂层球囊（DCB）已被证明与普通球囊血管成形术相比可提高通畅率并降低再血管化率。DCB 通过改进球囊涂层技术不断发展，这些技术最大限度地减少了进入血流的颗粒数量，同时最大限度地保留了药物并保持了血管愈合特性。在此背景下，很明显，用于股浅动脉的抗增殖药物的未来将集中在改进设备涂层材料上，以提高药物输送效率。Ranger DCB 系统最近获得了美国 FDA 的批准使用。本综述讨论了 DCB 的背景以及 Ranger DCB 如何基于实验和临床数据建立在这些先前平台之上。
